Ocugen Patient Engagement

Ocugen Patient Engagement A fully integrated, patient-centric biotech company focused on vaccines and gene therapies.

Promising early safety and efficacy results continue to reinforce the potential of OCU410ST for Stargardt disease. At 12...
06/05/2026

Promising early safety and efficacy results continue to reinforce the potential of OCU410ST for Stargardt disease.

At 12 months, treated eyes demonstrated a 54% reduction in atrophic lesion growth, while 100% of evaluable treated eyes showed stabilization or improvement in visual function and achieved a +6 letter gain in visual acuity.

Hear directly from an OCU410ST clinical trial participant and learn more about their experience: https://bit.ly/3Q9CBiI

What is Retinitis Pigmentosa (RP)?RP is a group of rare, inherited eye diseases that cause progressive vision loss over ...
06/04/2026

What is Retinitis Pigmentosa (RP)?

RP is a group of rare, inherited eye diseases that cause progressive vision loss over time. People with RP may have trouble seeing at night and can gradually lose their side vision. More than 150 genetic mutations can cause RP, making it difficult to treat.

OCU400, Ocugen's lead novel modifier gene therapy, is designed to address over 98% mutations associated with RP with a single, one-time treatment. By supporting retinal cells, OCU400 has the potential to preserve and restore vision for people living with RP, for whom no treatment currently exists.

Awareness starts with a conversation. Share this post to help educate others about RP.

What is Stargardt disease?Stargardt disease is a rare inherited eye disease that slowly takes away central vision, makin...
05/18/2026

What is Stargardt disease?

Stargardt disease is a rare inherited eye disease that slowly takes away central vision, making it harder to read, recognize faces, and see the world clearly over time. It affects the retina, the light-sensitive tissue in the back of the eye that helps us process what we see.

Ocugen is studying a potential gene therapy, OCU410ST, with the hope of slowing the progression of disease and helping protect vision for the future. Every step forward brings hope to individuals and families affected by inherited retinal diseases.

Like and share this post to help more people learn about Stargardt disease and inherited retinal diseases.

During , Ocugen shared a poster presentation on reducing variability in quantitative autofluorescence measurements thro...
05/11/2026

During , Ocugen shared a poster presentation on reducing variability in quantitative autofluorescence measurements through automation for & . Proud to support innovation advancing research for blindness diseases.

ARVO

What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual funct...
05/01/2026

What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual function.

If you found this helpful, share it with someone who should know more about EZ.

04/22/2026

Susan, an OCU410ST clinical trial participant, shares her experience after treatment for Stargardt disease, reporting stabilization in the treated eye while the untreated eye continued to decline.

Now being studied in the Phase 2/3 GARDian3 pivotal confirmatory trial, OCU410ST is designed to slow or potentially even reverse disease progression.

Turn on notifications for Ocugen by clicking the "Follow" button in the top right corner of our Facebook to stay up to date on patient journeys and more Ocugen news.

Today, we celebrate , marking its 115th anniversary. This global observance recognizes the social, economic, cultural, ...
03/08/2026

Today, we celebrate , marking its 115th anniversary. This global observance recognizes the social, economic, cultural, and political achievements of women around the world.

Across Ocugen, we are proud to recognize the women on our leadership team and all women of Ocugen whose expertise, knowledge, and dedication help drive innovation and advance our mission. From scientific discovery to operational leadership, their contributions play a vital role in progressing our novel modifier gene therapy platform and delivering hope to patients. We shine a light on women who continue to inspire progress in biotech and make a meaningful impact every day.

From our office in Malvern, PA, to our office in Hyderabad, India, we support ! 💙💚🩷💜Rare Disease Day is a time to raise...
02/28/2026

From our office in Malvern, PA, to our office in Hyderabad, India, we support ! 💙💚🩷💜

Rare Disease Day is a time to raise awareness and reaffirm our commitment to patients and families living with inherited retinal diseases. To show support and unity, our team wore variations of the official Rare Disease Day colors. Wearing these colors is a simple but meaningful way to stand with the rare disease community and the patients we serve.

The Ocugen team is driven by purpose every day, advancing our innovative novel modifier gene therapies for inherited retinal diseases including retinitis pigmentosa and Stargardt disease, where significant unmet medical needs remain.

Today, and every day, we stand with the rare disease community and the patients who inspire our work.

Rare Disease Day

02/25/2026

During , we recognize the impact of inherited retinal diseases and the urgent need for new treatment options.

Driven by our passion to put patients at the center and develop innovative gene therapies for major blindness diseases, Ocugen is advancing OCU400, our lead novel modifier gene therapy candidate designed to address all gene mutations associated with retinitis pigmentosa (RP) with a single, one-time injection. We plan to begin the rolling submission for the OCU400 Biologics License Application this year and potentially provide a treatment option for the 98% of RP patients for whom no therapy exists. Hearing the positive impact OCU400 is having on the lives of clinical trial participants propels us forward every day.

Learn more about Manny’s journey: https://bit.ly/4aQL9Bw

Today is International Day of Women and Girls in Science, a moment to raise awareness about the need for gender equality...
02/11/2026

Today is International Day of Women and Girls in Science, a moment to raise awareness about the need for gender equality in STEM and celebrate women who have been successful in the field. We are deeply encouraged by the brilliance, curiosity, and breakthroughs driven by women in STEM—across our Ocugen team and in every girl exploring a future in science.

We believe progress accelerates when more voices are included. We’re proud to champion courageous innovation in pursuit of better health and hope for patients and communities.

Address

11 Great Valley Parkway
Malvern, PA
19355

Website

Alerts

Be the first to know and let us send you an email when Ocugen Patient Engagement posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Ocugen Patient Engagement:

Shortcuts

Share

Category